Manuel Cano1, Ying Huang2. 1. Department of Social Work, University of Texas at San Antonio, 501 W. César E. Chávez Blvd., San Antonio, TX, 78207, USA. Electronic address: manuel.cano@utsa.edu. 2. Department of Demography, University of Texas at San Antonio, 301 South Frio Street, San Antonio, TX, 78207, USA.
Abstract
BACKGROUND: Over the course of the past decade, psychostimulants such as methamphetamines have been increasingly reported in overdose deaths in the United States (US). Methamphetamine use has recently risen among individuals who use opioids, yet it is unclear what role the opioid crisis has played in the increase in psychostimulant-involved overdose mortality in states across the US. METHODS: Mortality data from the Centers for Disease Control and Prevention were used to examine recent state-level changes in overdose deaths involving psychostimulants with abuse potential, excluding cocaine. Psychostimulant-involved overdose mortality rates, changes in rates, and opioid co-involvement were compared by state and plotted on choropleth maps. Ordinary least squares regression analyses were used to test the associations between a state's psychostimulant-involved overdose mortality rate change and several state-level indicators related to the opioid crisis. RESULTS: From 2015/2016-2017/2018, significant increases in psychostimulant-involved overdose mortality rates were observed in 42 of 47 states with data available. Each of the three state-level indicators examined in the study (opioid prescribing rate in 2012, past-year prevalence of opioid use disorder from 2015-2018, and increase in drug overdose mortality during the earliest stages of the opioid crisis from 1999-2012) was positively associated with the absolute rate change in psychostimulant-involved overdose mortality from 2015/2016-2017/2018. CONCLUSIONS: Although deaths involving methamphetamine have historically been primarily concentrated in the western US, results of the study reflect the alarming increase in psychostimulant-involved overdose mortality across the nation, especially in some of the states heavily impacted by the opioid crisis.
BACKGROUND: Over the course of the past decade, psychostimulants such as methamphetamines have been increasingly reported in overdose deaths in the United States (US). Methamphetamine use has recently risen among individuals who use opioids, yet it is unclear what role the opioid crisis has played in the increase in psychostimulant-involved overdosemortality in states across the US. METHODS:Mortality data from the Centers for Disease Control and Prevention were used to examine recent state-level changes in overdose deaths involving psychostimulants with abuse potential, excluding cocaine. Psychostimulant-involved overdosemortality rates, changes in rates, and opioid co-involvement were compared by state and plotted on choropleth maps. Ordinary least squares regression analyses were used to test the associations between a state's psychostimulant-involved overdosemortality rate change and several state-level indicators related to the opioid crisis. RESULTS: From 2015/2016-2017/2018, significant increases in psychostimulant-involved overdosemortality rates were observed in 42 of 47 states with data available. Each of the three state-level indicators examined in the study (opioid prescribing rate in 2012, past-year prevalence of opioid use disorder from 2015-2018, and increase in drug overdosemortality during the earliest stages of the opioid crisis from 1999-2012) was positively associated with the absolute rate change in psychostimulant-involved overdosemortality from 2015/2016-2017/2018. CONCLUSIONS: Although deaths involving methamphetamine have historically been primarily concentrated in the western US, results of the study reflect the alarming increase in psychostimulant-involved overdosemortality across the nation, especially in some of the states heavily impacted by the opioid crisis.
Authors: Ryan McNeil; Taylor Fleming; Alexandra B Collins; Sandra Czechaczek; Samara Mayer; Jade Boyd Journal: Drug Alcohol Depend Date: 2021-03-18 Impact factor: 4.492
Authors: Manal Mansoor; Ryan McNeil; Taylor Fleming; Allison Barker; Sheila Vakharia; Kimberly Sue; Andrew Ivsins Journal: Int J Drug Policy Date: 2022-01-31
Authors: Joshua C Zamora; Hudson R Smith; Elaine M Jennings; Teresa S Chavera; Varun Kotipalli; Aleasha Jay; Stephen M Husbands; Alex Disney; Kelly A Berg; William P Clarke Journal: Pharmacol Res Perspect Date: 2021-12